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1. Introduction 
Cognitive behavior therapy (CBT) is the treatment of choice for panic disorder with 
agoraphobia (PDA). Numerous studies have been conducted on the short- and long-term 
effectiveness of CBT. Treatment effectiveness could range as low as 25% and as high as 90% 
(e.g., Barlow et al. 1989; Black et al., 1993; Fava et al., 1995; Margraf et al., 1993; Öst & 
Westling, 1995; Shear et al., 1994; Taylor et al., 1996).  Nevertheless, most studies have 
concluded that CBT appears to be the most effective treatment to date in reducing panic-
related symptomatology in the short- and long-term (Clark et al., 1994; Craske et al., 1991; 
Fava, et al., 1995). However, some clients continue to experience anticipatory anxiety and 
avoidance following CBT (Clark et al., 1994; Craske et al., 1991; Klosko et al., 1990). Brown and 
Barlow (1995) conducted a long-term outcome study using stringent criteria for treatment 
efficacy. Although the treatment had produced substantial improvements, their findings 
revealed that only 20.6% of their sample could be considered as treatment success after two 
years. One of their recommendations for future studies was to examine predictors of treatment 
response. Following up on these recommendations, the present study aims to determine why 
some clients do not respond to CBT or only show partial benefits. 
Outcome studies have examined the impact of different client variables such as motivation, 
personality traits, socio-demographic characteristics, diagnosis, and intelligence to name a 
few. The important role of client variables in psychotherapy has been confirmed in 
numerous studies since the 1940's (see Garfield, 1986 and Lambert & Assay, 1984). Highlen 
and Hill (1984) conducted an extensive review on the effects of psychotherapy and 
concluded that client characteristics are the most important and influential factors relating to 
treatment outcome and to long-term improvement (Highlen & Hill, 1984). 
Several variables listed by Highlen and Hill (1984), have been important in predicting 
treatment outcome and long-term improvement in PDA. For instance, the severity of 
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agoraphobic avoidance and depressed mood have been detected as predictors in the 
maintenance of panic attacks (Keijsers et al., 1994). Comorbidity has also been a determining 
factor that predicts poorer outcome in PDA after cognitive-behavior therapy and 
pharmacologic treatment have been administered (Keijsers et al., 1994; Pollack et al.,1994; 
Pollack et al., 1993). The use of "safety behaviors" has been found to reduce the effectiveness 
of exposure (Wells et al., 1995). Safety behaviors may include both behaviors and objects 
that are designed to help patients prevent their feared consequences from coming true. Such 
behaviors may include carrying water, chewing gum, listening to the radio, standing near a 
wall (in case one experiences symptoms of dizziness), and other similar behaviors that help 
them cope with their symptoms. Finally, anxiety sensitivity, an expectancy variable, has 
been associated with poorer outcome and relapse in patients with PDA (Keijsers et al., 1994; 
Reiss, 1991; Reiss et al., 1986; Schmidt et al.,1997). 
Individuals with PDA live in anticipation or expectation of the next panic attack and may 
restructure their lifestyle in response to this anticipation. Panic disorder patients will anticipate 
with fear that their bodily sensations associated with panic attacks will result in harmful 
psychological, somatic or social consequences (Craske & Barlow, 1993). Anxiety sensitivity is 
this belief that the experience of anxiety will cause them harm. (Reiss, 1991; Reiss et al., 1986). 
Anxiety sensitivity arose out of research conducted on motivation to avoid feared objects, 
situations or physical symptoms (Reiss, 1991). From this research, Reiss' expectancy theory 
(Reiss, 1991; Reiss & Havercamp, 1996; Reiss et al., 1986) emerged which proposed that fear is 
composed of two distinct factors: expectations (what one expects will happen to him/her) and 
sensitivities (why one is afraid of the expected occurrence). According to this theory, 
individuals may hold danger expectancies (e.g., "I expect to get bitten by that dog"), 
expectations of being socially evaluated ("I expect others to laugh at me") and anxiety 
expectancies (e.g., "I expect to have a panic attack if I go on the subway"). With regards to 
sensitivity, individuals may possess sensitivities regarding injury (e.g., "I expect to die from 
an infection if the dog bites me"), social evaluation (e.g., "I expect to turn red if they laugh at 
me") and anxiety (e.g., "I expect to have a heart attack if I panic"). While expectations and 
sensitivities vary from one individual to another, they seem to be particularly elevated in 
individuals with panic disorder (e.g., Reiss, 1991; McNally, 1992; Taylor et al., 1992). The 
above studies reviewed on expectancies indicate that they may be important contributors to 
PDA development, especially with respect to anxiety sensitivity (Reiss et al., 1986; Schmidt 
et al., 1997). 
Expectancy theory further postulates that anxiety expectancy stems from learned 
experiences that a given stimulus will generate anxiety or fear (Reiss & McNally, 1985). 
Nevertheless, a person need not experience anxiety in a particular situation in order to 
anticipate it. Certain situations may come to be associated with fear or anxiety after an 
individual has witnessed someone having a panic attack. Conversely, it is believed that 
anxiety sensitivity may be developed through learned experiences (Donnell & McNally, 
1990) and inherited through biological factors (Reiss & McNally, 1985).  For instance, 
although Donnell and McNally (1990) found that participants with high anxiety sensitivity 
were more likely to have experienced both a personal and family history of panic, two-thirds 
had never suffered a panic attack. In addition, findings from a retrospective study on the 
origins of anxiety sensitivity suggested that participants with high levels of anxiety sensitivity 
may have learned to catastrophize about the occurrence of bodily symptoms through parental 
reinforcement of sick-role behavior related to physical symptoms rather than anxiety-related 
symptoms (Watt et al., 1998). Schmidt and colleagues (1997) also revealed that anxiety 
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sensitivity predicts the development of panic and other anxiety symptoms independent of 
history of panic and trait anxiety. Thus, anxiety sensitivity is not considered a consequence of 
experiencing a panic attack, but rather a predisposing bio-psycho-social factor to developing 
panic. This suggests that an individual who experiences a panic attack but does not develop 
panic disorder may not have the biological markers nor the psychological and social attributes 
to developing panic disorder. This is somewhat consistent with Clarke's (1986) cognitive 
model of panic that posits that the development and maintenance of panic arise from a fear 
that bodily sensations will lead to harmful consequences. 
Several studies have demonstrated that a greater association exists between anxiety 
expectancy and avoidance behavior, rather than with the occurrence of panic attacks and 
avoidance (e.g., Cox et al., 1995; Cox et al., 1991; Craske et al., 1988; Whittal & Goetsch, 
1997). As expectation of panic increases, so does avoidance. This finding is also supported 
by Craske and Barlow’s (1988) hypothesis suggesting a greater relationship between 
avoidance behavior and anxiety expectancy. 
Treatments aimed at diminishing the expectation of anxiety may also be effective in 
reducing the amount of fear actually experienced by the individual (e.g., Kirsch et al., 
1983). For instance, Kirsch and colleagues (1983) succeeded in diminishing the amount of 
fear experienced in snake phobic patients through systematic desensitization and through 
an expectancy modification procedure. They concluded that the level of fear experienced 
by individuals with a snake phobia varies as a function of anxiety expectancy. Southworth 
and Kirsch (1988) also found that when the expectations of the occurrence of anxiety are 
reduced, patients with agoraphobia experienced less fear. These findings suggest that 
when clients expect to experience anxiety and they do not after several sessions of 
exposure, their fear ultimately diminishes. Changing expectations may have a direct impact 
on symptoms. 
Earlier studies on the effects of expectancies on outcome mostly focussed on prognostic 
expectations (i.e., the probability of a therapeutic success) that clients have when they enter 
into treatment (e.g., Frank, 1959; Goldstein & Shipman, 1961; see Goldstein, 1962; Piper & 
Wogan, 1970). However, in a review on psychotherapy, Perotti and Hopewell (1980) 
concluded that although expectancy effects are important in various interventions including 
systematic desensitization, pre-treatment expectations have little effect. Measuring 
expectations both at pretherapy and during the early treatment phase may not only provide 
information on whether clients can change their expectations but it may also shed some light 
on the impact these cognitive shifts have on outcome. After several sessions of therapy, 
expectations may shift towards a positive direction if clients perceive improvement or they 
may shift towards a negative direction if no benefits are noticed (Weiner, 1982). 
The research on panic disorder with agoraphobia has established the importance of 
expectancies in the development and maintenance of PDA (Ehlers, 1995; Maller & Reiss, 
1992; Schmidt et al., 1997; Watt et al., 1998). However, there is a paucity of data examining 
the differential effects of distinct types of expectancies (i.e., anxiety expectancy and 
sensitivity, avoidance expectancy) on initial severity and outcome of PDA using a cognitive-
behavioral treatment. Studies examining possible predictors in treatment outcome have 
determined that pre-symptom severity has an impact, especially pre-treatment agoraphobic 
avoidance and longer duration (e.g., Basoglu et al., 1994; de Beurs et al., 1995; Williams, & 
Falbo, 1996). However, no study to our knowledge has examined the differential impact of 
symptom severity and expectancies on cognitive-behavior therapy outcome of panic 
disorder with agoraphobia. Examining the relative contribution of these variables may 
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foster a greater understanding as to why some PDA clients show partial or no response to 
CBT. This may enable therapists to better prepare their treatment plan. 
There were several objectives to this study. First, we examined the impact of different types 
of expectancies on pre-treatment symptom severity. Expectancies that were examined 
included anxiety sensitivity, anxiety expectancy and prognostic expectancy as measured by 
avoidance expectancy (i.e., expectancy of avoidance at the end of treatment). Symptom 
severity was measured in terms of frequency of catastrophic cognitions during a panic 
attack, degree of fear of symptoms already experienced during a panic attack, panic 
symptomatology, avoidance, and by depressive symptoms. It was predicted that the 
severity of baseline expectancy would be associated with baseline symptom severity. 
Second, we examined the impact of the initial treatment phase scores in contrast to baseline 
scores on outcome. With respect to symptoms, our hypothesis is consistent with theories on 
in-session change in cognitive-behavior therapy that suggest that shifts in symptoms during 
sessions are better predictors of outcome than pretreatment severity (see Muran et al., 1995). 
We predicted that initial treatment phase symptom scores would be better predictors of 
outcome than baseline scores. With respect to expectancies, it was hypothesised that early 
treatment phase scores would be better predictors of outcome than baseline. After being 
exposed to several components of therapy, it is assumed that participants will adjust their 
expectations to be more consistent with the information received in the first few sessions. 
Finally, we examined the contribution of expectancies above and beyond the contribution of 
symptoms on the outcome of PDA following a cognitive-behavior therapy.  
2. Method 
2.1 Participants 
The sample consisted of 49 participants (14 males, 35 females) with a principal DSM-IV 
(Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; American Psychiatric 
Association, 1994) diagnosis of panic disorder with agoraphobia. Sixteen participants 
dropped out from pre- to post-treatment. Eleven males and 22 females completed the study. 
The mean age of the initial sample was 39.3 years  (SD = 11.19; range: 19 - 65 years) and the 
mean education level was 11.6 years (SD = 3.06). The average number of years of marriage 
or cohabitation was 12.3 years (SD = 11.98). There were 71.5% of the participants who were 
either married or cohabiting, 22.4% were single, 2% were separated or divorced and 2% 
were widowed. Most participants (n = 31; 63.3%) were taking psychoactive medication for 
their panic attacks. Twenty-three participants were recruited from two specialised 
outpatient anxiety disorder clinics in Montreal: the Douglas Hospital Anxiety Clinic (n = 8) 
and the Centre for Intervention for Cognitive Behavioral Therapy at Louis-H. Lafontaine 
Hospital (n = 15). The remaining participants were recruited from advertisements in the 
local newspapers (n=26). 
Patients included in the study met the following criteria: (a) a primary DSM-IV diagnosis of 
PDA assigned by one of the psychiatrists; (b) a primary diagnosis of PDA with a clinical 
severity rating of 4 or above on a scale ranging from 0 (none) to 8 (very severely disturbing-
disabling), established by administering the Anxiety Disorders Interview Schedule for DSM-
IV, Lifetime Version (ADIS-IV-L; DiNardo, Brown, & Barlow, 1994),  (c) a secondary DSM-
IV axis I diagnosis with an assigned ADIS-IV-L clinical severity rating which ranges from 
moderate to severely disabling (i.e., 4 to 6) and consists of a rating of 2 or more levels lower 
than the PDA rating, (d) age between 18 and 65 years, and (e) at least a mean of 1 panic 
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attack per week in the 3 weeks prior to participation in the assessment. Exclusion criteria 
included: (a) the presence of substance-related, psychotic and bipolar disorders and any 
organic brain conditions as evaluated by the psychiatrists; and, (b) the presence of any 
unstable medical condition considered by the evaluating psychiatrist to be mistaken for 
anxiety symptoms (e.g., thyroid disorders, asthma, cardiovascular diseases, etc).  
The average duration of PDA was 13 years (SD = 10.4; range: 1 - 40 years). Secondary 
diagnoses as assessed by the psychiatrists and the ADIS-IV-L included other anxiety 
disorders, hypochondriasis and affective disorders. Twenty-four patients also met criteria 
for one or more of the following secondary diagnoses ranging from moderate (i.e., 4) to 
severely disabling (i.e, 6): generalized anxiety disorder (n = 13), dysthymia (n = 4), social 
phobia (n = 3), post traumatic stress disorder (n = 3), specific phobia (n = 2), obsessive 
compulsive disorder (n = 2), hypochondriasis (n = 2), major depressive disorder (n = 1), 
and mania (n = 1). For all secondary diagnoses, the ADIS-IV-L clinical severity rating was 
2 or more levels lower than the PDA rating. Participants accepted in the study with a 
secondary diagnosis had disorders that were not in immediate need of treatment as 
assessed by the psychiatrists.  
A high percentage of patients (n = 31; 63.3%) were taking psychoactive medication. 
Medication needs of the patients were evaluated during the evaluation with the psychiatrist. 
Participants under pharmacological treatment for anxiety, at the time of the evaluation, 
were permitted to participate only after medication had been stable for 6 weeks prior to 
treatment. Participants were asked to maintain the same dosage throughout the treatment 
phase of the study to allow for evaluation of the effects of psychotherapy above the effects 
of these drugs (e.g., Brown & Barlow, 1995). Participants taking medication were not 
asked to discontinue pharmacotherapy before treatment since (a) many individuals would 
probably not participate because they would not want to stop taking their medication 
before treatment, and (b) discontinuing medication during treatment may lead to an 
increase in panic attacks which may affect responses given on baseline measures (Öst & 
Westling, 1995).  
2.2 Treatment 
Treatment was administered by experienced clinical psychologists. Co-therapists consisted 
of doctoral students in clinical psychology. They had experience in cognitive-behavior 
therapy, had been trained in administering the group treatment for PDA and were closely 
supervised by the second author of this study. All therapists followed a written manual 
which included the protocol for each session. There were a total of 6 groups that consisted of 
a maximum of 10 participants. Cognitive behavior group therapy was administered based 
on the Panic Control Treatment developed in SUNY Albany (Craske & Barlow, 1990). The 
treatment consisted of 14 weekly, 3-hour sessions and comprised five major components: (a) 
education and information concerning the nature, etiology and maintenance of panic; (b) 
cognitive restructuring (Beck, 1988) aimed at demystifying symptoms and fears and helping 
participants identify, monitor and change mistaken appraisals of threat that precipitate 
panic attacks and maintain avoidance behaviors; (c) training in diaphragmatic breathing as a 
way of reducing physical symptoms that often trigger panic attacks; (d) interoceptive 
exposure exercises designed to reduce fear of somatic sensations through repeated exposure 
to bodily sensations associated with panic; and (e) prolonged and repeated in vivo exposure 
to feared situations. Participants were also expected to practice techniques and read relevant 
material on PDA in between sessions. 
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2.3.1 Symptom measures 
Participants completed a battery of self-reported questionnaires commonly used in PDA 
research. The following measures on symptom severity have demonstrated acceptable 
psychometric properties. A French version of these questionnaires was utilised in the 
current study. 
Severity of cognitive panic symptoms was assessed by the Body Sensations Questionnaire 
(BSQ; Chambless et al., 1984) and Agoraphobia Cognitions Questionnaire (ACQ; Chambless 
et al., 1984). The BSQ is a 17-item questionnaire that measures level of fear concerning 
bodily sensations that have been experienced during a panic attack. The ACQ consists of 14 
items measuring the frequency of catastrophic thoughts during a panic attack. Both 
measures are rated on a 5-point Likert-type scale. Coefficient alpha for the BSQ in this study 
was estimated at .88 and for the ACQ at .79. These two measures assess fear of fear as a 
consequence of panic experiences. The psychometric properties of the French-Canadian 
versions employed in this study are equivalent to those of the English version  (Stephenson 
et al., 1998; Stephenson et al., 1999). 
One of the three measures provided by the Mobility Inventory for Agoraphobia (MIA; 
Chambless et al., 1985) was used in this study: the severity of agoraphobic avoidance 
behavior when the person is alone. The MIA-Alone is a 26-item questionnaire rated on a 5-
point Likert-type scale. This study calculated the coefficient alpha at .93.  Psychometric 
properties of the French-Canadian version have been found to be similar to those of the 
English version  (Stephenson et al.,  1997).   
Physical and cognitive symptoms experienced during the past week were assessed using the 
Beck Anxiety Inventory (BAI; Beck et al., 1988). This 21-item questionnaire, rated on a 4-
point scale, examines the degree to which participants were affected by their symptoms over 
the past week. In this study, internal consistency was estimated at .93.  
Depressive symptoms were measured using a French version of the Beck Depression 
Inventory-II (BDI-II; Beck et al., 1996). The BDI-II is composed of 21 items rating depressive 
symptoms for a two-week period, on a 4-point scale.  In the current study, internal 
consistency for this measure was estimated at .91.  In 1961 and 1978 the French-Canadian 
version of the BDI was validated (Gauthier et al., 1982; Bourque & Beaudette, 1982). There is 
no current validation study for the French-Canadian version of the BDI-II, however, we 
chose to use the latter in this study because there is greater consistency with the DSM-IV 
criteria for major depressive disorder. 
2.3.2 Expectancy measures 
All expectancy measures for this study were translated into French using forward and back 
translation techniques (Vallerand, 1989; see Table 2 for overall distribution of all expectancy 
measures). The following expectancy measures have not yet been validated for their 
psychometric properties.  
2.3.2.1 Anxiety expectancy 
A section of the Panic Attack Questionnaire (PAQ; Norton et al., 1986), containing 36 items, 
was used to assess anxiety expectancy. Participants rate on a scale of 0 (never) to 4 (very 
likely) how much they expect a future panic attack to occur in a particular situation 
regardless of whether or not they have previously experienced a panic attack in that 
situation. Internal consistency of the French version (Bélanger & Katerelos, 1998) of this 
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questionnaire using the current sample was estimated at .91. This measure will be referred 
to as Panic Attack Questionnaire-Expectancy (PAQ-E). 
2.3.2.2 Anxiety sensitivity 
Anxiety Sensitivity Index (ASI; Reiss et al., 1986) is a 16-item questionnaire, rated on a 5-
point Likert-type scale. It measures fear of anxiety and has been specifically associated with 
agoraphobia (see Taylor, 1993). The items assess the level of expected somatic, psychological 
or social harm that may occur as a result of anxiety symptoms. However, a history of panic 
attacks is not an essential component for developing negative beliefs about the harmful 
effects of anxiety. The internal consistency of the questionnaire has been estimated at .88 
(Cox et al., 1996) and a two-week test-retest reliability has been computed at .75 (Reiss et al., 
1986). Psychometric properties of the French-Canadian version have been found to be 
similar to those of the English version (Marchand et al., 1999). Internal consistency for the 
French translation of the ASI was calculated at .81 in this study.  
2.3.2.3 Avoidance expectancy 
An adaptation of the Mobility Inventory for Agoraphobia-Alone (MIA-A; Chambless et al., 
1985) was used to assess prognostic expectations (with respect to avoidance behavior)(i.e., 
the probability of a therapeutic success). The Expectancy Mobility Inventory for 
Agoraphobia-Alone (EMIA-A) measures the degree of expected agoraphobic avoidance 
behavior following therapy (Katerelos et al., 1998). The same items as the MIA-A were 
administered along with the corresponding 5-point scale. However, the adapted version 
contains questions reformulated into expectancies (e.g., "After the treatment, I expect 
to…never avoid going to the movies"). With the current French sample and with the items 
reformulated into expectancies, internal consistency when alone was at 95.  
2.4 Procedure 
Participants recruited from advertisements in the local newspapers were screened using a 
brief telephone interview in order to determine suitability. Those who were considered 
appropriate for the study were invited to one of the clinics to take part in a structured 
interview. If the criteria for a primary diagnosis of PDA were satisfied according to the 
ADIS-IV-L, participants were evaluated by a psychiatrist from one of the two collaborating 
clinics to confirm the diagnosis. A battery of questionnaires was completed after the DSM-
IV diagnosis of PDA had been confirmed. Those recruited directly from the clinics had 
already received a diagnosis of PDA by one of the psychiatrists. The ADIS-IV-L was 
subsequently administered in order to rule out an additional Axis I primary diagnosis and 
to confirm the  initial DSM-IV diagnosis given by the psychiatrist. All participants provided 
informed consent prior to the structured interview with the ADIS-IV-L. Those who did not 
meet the criteria of the study were appropriately referred elsewhere. 
Expectancies were assessed prior to therapy (T1) and after patients had completed 4 sessions 
(T2; initial treatment phase). Symptom severity was measured prior to therapy (T1), 4 
sessions after therapy had begun (T2; initial treatment phase) and after the last session (T3). 
By session four, clients receive (a) education and information concerning the nature, 
etiology and maintenance of panic, as well as information on the impact PDA has on social 
functioning, daily activities, family and work; (b) symptom demystification, (c) training in 
diaphragmatic breathing, (d) basic coping strategies to deal with panic, and (e) information 
on the role of irrational thoughts in PDA. 
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3.1 Sample characteristics 
Of the 49 patients who began the treatment, 33 completed. An analysis of variance 
(ANOVA) detected no difference between dropouts and completers in symptomatology, 
expectancies, duration of PDA, gender or sociodemographic variables. In addition, analyses 
of variance did not reveal any significant differences between those who took medication 
and those who did not on gender, sociodemographic variables, pre-treatment expectancy 
measures nor on most symptom severity measures (p > .05). No significant differences were 
found between clients referred from either of the two clinics and those referred from the 
local newspapers on any sociodemographic or expectancy variable, and for most 
symptomatology variables (p > .05). However a univariate ANOVA revealed a significant 
main effect for group for the BDI-II measures F(2, 45) = 4.1, P < .023. Bonferroni post hoc 
comparisons demonstrated significantly higher BDI-II scores for the 8 participants selected 
from the Douglas Hospital Anxiety Clinic (M=24.1, SD=14.5) in contrast to those chosen 
from local newspapers (M=13.5, SD=9.2) (p < .05). 
3.2 Dependent variables 
The dependent variables (i.e., post-treatment measures; T3) approached a normal 
distribution. The means and standard deviations for the dependent variables were as 
follows: Body Sensations Questionnaire (BSQ) (M = 32.5, SD = 2), Agoraphobia Cognitions 
Questionnaire (ACQ) (M = 23.7, SD = 1.2), Beck Anxiety Inventory (BAI) (M = 11.4, SD = 
1.9), Mobility Inventory for Agoraphobia-Alone (MIA-A) (M = 49.4, SD = 4.3) and the Beck 
Depression Inventory (BDI-II) (M = 8.2, SD = 1.3).  
3.3 Predictors of pre-treatment (T1) symptom severity scores 
Our first objective was to examine the impact of anxiety sensitivity (ASI), anxiety expectancy 
(PAQ-E) and avoidance expectancy (EMIA-A) on pre-treatment symptom severity.  
Stepwise regression analyses were conducted using data from the initial 49 participants in 
order to determine predictors of pre-treatment symptom severity. Correlations were 
calculated for the sample (see Table 1) and only measures that were significant at p < .01 
were entered into the regression equations. The first regression analysis used the BSQ (T1) 
as the dependent variable. The findings revealed that the ASI (T1) significantly entered into 
the equation [r2 change = .44, F(1, 46) = 35.9, P < .001)]. The PAQ-E did not contribute to the 
prediction model. 
The second regression analysis used the ACQ (T1) as the dependent variable. The ASI [r2 
change = .09, F(1, 45) = 8.1, P < .01)] was once again the only significant predictor variable. 
The PAQ-E failed to significantly enter into the equation. 
The third regression analysis examined to what degree the BAI (T1) was determined from 
expectancy scores. The findings revealed that PAQ-E (T1) [r2 change = .17, F(1, 46) = 9.3, P < 
.01)] significantly entered into the regression equation but the ASI failed to add to the 
prediction model. 
A fourth regression analysis was performed to determine to what degree the MIA-A(T1) 
scores could be predicted from expectancy scores. The findings revealed that both the PAQ-
E (T1) [r2 change = .24, F(1, 47) = 14.8, P < .001)] and the EMIA-A (T1) [r2 change = .08, F(1, 
46) = 5.2, P < .05)] significantly entered into the equation.  
The BDI-II (T1) was significantly correlated with one expectancy measure: the ASI (r=.49, p 
< .001).  
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None of the pre-treatment expectancy measures were significantly associated with duration 
of PDA and with number of panic attacks in the past month (p > .05).  
 
























.19 .32* .21 .38** .19 
Note: Ns may vary from 47 to 49 due to missing data. 
*p < .05, **p < .01, ***p< .001 
Table 1. Correlations Between Pre-treatment Symptom Severity and Expectancy. 
3.4 Pretreatment (T1) vs. initial treatment phase (T2): symptom severity and 
expectancy measures 
In order to verify our second hypothesis indicating that initial treatment phase scores would 
be better predictors of outcome than pre-treatment scores, we first performed t-tests to 
determine whether there were any changes from pre- to initial treatment phase. There was 
considerable improvement from pre-treatment to session 4 (i.e., initial treatment phase) for 
all symptom severity and expectancy measures. One exception was noted for the 
Expectancy Mobility for Agoraphobia Inventory-Alone (EMIA-A). Changes in scores from 
pre-treatment to session 4, means, standard deviations, and ranges are presented in Table 2. 
All measures approximated a normal distribution. 
 
 Pre-treatment Scores  Session 4 Scores   
Variables M SD Range   M SD Range t df 
Symptom Measures    
Body Sensations Questionnaire 50.4 14.5 17-85  42.6 15.1 19-75 2.86** 37 
Agoraphobia Cognitions 
Questionnaire 
35.7 9.4 17-60  30 9.7 17-58 4.05*** 7 
Beck Anxiety Inventory 28.1 14.8 0-55  16.4 10.6 1-41 5.11*** 36 
Mobility Inventory for Agoraphobia-
Alone 
85.7 24.2 46-130  67.6 28.2 31-129 7.23*** 37 
Beck Depression Inventory 16.4 10.1 2-44  12.7 10.4 0-36 -2.26* 37 
Expectancy Measures      
Anxiety Sensitivity Index 34.1 10.8 11-58  25 11.6 2-48 4.68*** 39 
Panic Attack Questionnaire -
Expectancy 
72.8 24.7 8-120  52.3 23.8 0-117 5.22*** 40 
Mobility Inventory for Agoraphobia-
Alone Expectancy 
52.0 19.3 26-114  51.5 21.6 26-103 0.15 40 
Note: Ns may vary from 37 to 41 due to missing data. 
*p < .05, **p < .01, ***p< .001 
Table 2. Changes in Independent Variables from Pre-treatment to Initial Treatment Phase. 
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3.5 Treatment outcome 
Outcome data is provided for 33 patients. Significant improvements were detected from pre-
treatment to post treatment scores on all symptom severity measures (p < .001). There was no 
significant relationship between duration of PDA and post-treatment measures (p > .05). 
3.5.1 Predictors of pretreatment outcome 
Consistent with our second objective, the effect of initial treatment phase scores (T2) in 
contrast to baseline scores (T1) on treatment outcome was examined. Multiple regression 
analyses were first performed for symptom severity measures and then for expectancy. 
Subsequent regression analyses were performed to verify our final objective aimed at 
determining the contribution of expectations over the effects of symptoms on treatment 
outcome. Only factors that were significantly correlated at a conservative alpha of .01 were 













Body Sensations Questionnaire  .34* .28 .35* -.05 .47** 
Agoraphobia Cognitions Questionnaire .30 .28 .33 .08 .36* 
Beck Anxiety Inventory .28 .25 .33 .21 .45** 
Mobility Inventory for  
Agoraphobia-Alone 
.07 .37* .27 .72*** .14 
Beck Depression Inventory .61*** .49** .40* .31 .56*** 
Initial Treatment Phase (T2) 
Body Sensations Questionnaire  .63*** .43** .24 .31 .16 
Agoraphobia Cognitions Questionnaire .47** .47** .21 .43* .16 
Beck Anxiety Inventory .59*** .55** .67*** .29 .50** 
Mobility Inventory for Agoraphobia-
Alone 
.29 .28 .05 .77*** -.08 
Beck Depression Inventory .33 .30 .18 .08 .42* 
Note: Ns may vary from 31 to 33 for post treatment data, 37 to 38 for mid-treatment data and 48 to 49 
for pre-treatment data due to missing data and dropouts. BSQ = Body Sensations Questionnaire (T3); 
ACQ = Agoraphobia Cognitions Questionnaire; BAI= Beck Anxiety Inventory; MIA-A = Mobility 
Inventory for Agoraphobia-Alone; BDI = Beck Depression Inventory 
*p < .05, **p < .01, ***p< .001 
Table 3. Correlations between Dependent Variables and Independent Variables: Symptoms 
Measures 
3.5.2 Multiple regression analyses with symptom severity measures 
Hierarchical regression analyses were conducted to determine the extent to which 
variability in post-treatment (T3) symptomatology could be predicted from pre-treatment 
(T1) and initial treatment phase (T2) symptomatology measures. Initial treatment phase 
scores were entered into the first step followed by pre-treatment scores. The results in Table 
5 demonstrate that overall, pre-treatment did not significantly add to the prediction of post-
treatment severity, with the exception of the BDI-II.  Since initial treatment phase scores 
significantly improved from baseline, this suggests that changes in symptomatology are 
better predictors of outcome than pre-treatment severity.  
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II (T3) M SD Range 
Pre-treatment (T1) 
Anxiety Sensitivity Index .35 .18 .41* .04 .47** 34.4 10.6 11-58 
Panic Attack Questionnaire .24 .27 .26 .35* .10 73.1 23.5 8-120 
Mobility Inventory for 
Agoraphobia-Alone 
Expectancy .31 .23 .22 .41* .19 52.9 18.5 26-114 
Initial Treatment Phase (T2) 
Anxiety Sensitivity Index .65*** .57*** .37* .50** .57*** 24.7 11.6 2-48 
Panic Attack 
Questionnaire .76*** .59*** .52** .55*** .43* 52.3 23.8 0-117 
Mobility Inventory for 
Agoraphobia-Alone 
Expectancy .52** .55*** .30 .81*** .32 51.5 21.6 26-103 
Note: Ns may vary from 31 to 33 for post-treatment, 37 to 38 for mid-treatment and 48 to 49 for pre-
treatment data (i.e., M, SD and Range) due to missing data with treatment and dropouts between time. 
T3 = Post-treatment; BSQ = Body Sensations Questionnaire (T3); ACQ = Agoraphobia Cognitions 
Questionnaire; BAI= Beck Anxiety Inventory; MIA-A = Mobility Inventory for Agoraphobia-Alone; BDI 
= Beck Depression Inventory 
*p < .05, **p < .01, ***p< .001 
Table 4. Correlations between Dependent Variables and Independent Variables (i.e., 
Expectancy measures) 
To determine which individual measures were the best predictors of post-treatment 
symptomatology, significant regression analyses were re-ran for the BSQ (T3), ACQ (T3), 
and the BDI (T3). Variables that did not significantly contribute to the initial model were 
removed from the equations.  
Results for the BSQ post-treatment (T3), revealed that the BSQ (T2) [r2 change = .40, F(1, 28) 
= 18.3, P < .001)] and BAI (T2) [r2 change = .13, F(1, 27) = 7.6, P < .01)] were significant 
predictors in the model. 
Results for the ACQ post-treatment (T3) revealed that the BAI (T2)  [r2 change = .22, F(1, 28) 
= 7.7, P < .01)] and the ACQ (T2) [r2 change = .18, F(1, 27) = 8.1, P < .01)] were significant 
predictors of the ACQ (T3), accounting  for 18% and10% of the variance respectively. A 
regression analysis was performed with factors that reached significance for the BDI-II post-
treatment (T3). The BAI (T2) was entered into the first block and then the BDI-II (T1) was 
entered into the second. The findings revealed that pre-treatment depressive symptoms 
(BDI-II T1) [ r2 change = .17, F(1, 27) = 7.63, P < .01)] contributed above and beyond the 
effects of initial treatment phase anxiety symptoms (BAI T2) [ r2 change = .25, F(1, 28) = 9.38, 
P < .01)] in the prediction of post-treatment depressive symptoms (BDI-II T3). However, 
only pre-treatment depressive symptoms were significant predictors when the second 
model was retained. The BAI (T2) failed to reach significance. This suggests that severity in 
depression at baseline is a greater predictor of post-treatment depression when compared to 
any of the other measures taken after the fourth session (i.e., initial treatment phase). 
The BAI post-treatment ratings (T3) were significantly correlated with one measure: the BAI 
scores at the initial treatment phase (i.e., session 4) (r = .67, p < .001). 
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1 BSQ (T2) .53*** 9.7 3, 26 .10*  
  BAI (T2)    .13*    
  ACQ (T2)    .00 




1 BAI (T2) .40*** 8.8 2, 27 .18**  
  ACQ (T2)    .10*  




1 MIA-A (T2) .59*** 41.5 1, 29 .59*** 
 2 MIA-A (T1) .02 1.7 1, 28 .02 
Beck Depression 
Inventory (T3) 
1 BAI (T2) .25** 9.4 1, 28 .25**  
 2 BDI-II (T1) .21* 3.3 3, 25 .11*   
  BSQ (T1)    .01   
   BAI (T1)       .03     
Note: Ns may vary from 30 to 31 due to missing data 
BSQ = Body Sensations Questionnaire (T3); ACQ = Agoraphobia Cognitions Questionnaire; BAI= Beck 
Anxiety Inventory; MIA-A = Mobility Inventory for Agoraphobia-Alone; BDI = Beck Depression 
Inventory 
*p < .05, **p < .01, ***p< .001 
Table 5. Hierarchical Regression Analysis of Pre-treatment (T1) Symptomatology and Initial 
Treatment Phase (T2) Measures on Post-Treatment (T3) Symptomatology Measures 
3.5.3 Multiple regression analyses with expectancy measures 
In accordance with the second part of our second objective, hierarchical regression analyses 
were conducted to determine the extent to which variability in post-treatment 
symptomatology measures could be predicted from pre-treatment and initial treatment 
phase expectancy scores. Factors that were significantly correlated at the p < .01 level 
entered into the regression equations. Measures from the initial treatment phase (T2) were 
entered in the first block and baseline measures (T1) were entered in the second. Analyses 
were conducted for the BSQ (T3) and the BDI-II (T3) since they were the only measures that 
were significantly correlated (p < .01) with both pre-treatment and initial treatment phase 
expectancy measures (see Table 4). The results in Table 6 demonstrate that the initial phase 
session (T2; session 4) measures are significant predictors of the BSQ (T3) and the BDI-II 
(T3). Pre-treatment expectancy measures did not significantly add to the prediction model 
for these two dependent measures. To determine which initial treatment phase (T2) 
expectancy measures were the best predictors of post-treatment symptomatology, stepwise 
regression analyses were performed. 
We first examined the degree to which BSQ (T3) scores could be predicted from initial 
treatment phase expectancy scores. The PAQ-E (T2), the ASI (T2), and the EMIA-A (T2) 
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were entered into the equation. The results showed that anxiety expectancy as measured by 
the PAQ-E (T2) accounts for significant variance in the BSQ (T3) [r2 change = .58, F(1, 30) = 
41.4, P < .001)] , however, anxiety sensitivity (i.e., ASI T2) and avoidance expectancy (i.e., 
EMIA-A T2) failed to make a contribution to the model. 
A stepwise regression analysis was performed to determine to what degree post-treatment 
agoraphobic cognitions (i.e., ACQ T3) scores could be predicted from the initial treatment 
phase (T2) scores. The PAQ-E (T2), the ASI (T2), and the EMIA-A (T2) were entered into the 
equation. The findings revealed that the PAQ-E (T2) [r2 change = .35, F(1, 30) = 16.2, P < 
.001)] and the EMIA-A (T2) [r2 change = .08, F(1, 29) = 4.3, P < .05)] each account for 
significant variance in the ACQ (T3) ratings (i.e., 13% and 8% respectively). The ASI (T2) did 
not enter significantly on the third step.  
A stepwise regression analysis was conducted with EMIA-A (T2), PAQ-E (T2), and ASI (T2) 
as the independent measures and MIA-A post-treatment scores as the dependent measure. 
The findings showed that avoidance expectancy (i.e., EMIA-A T2) was the best predictor [r2 
change = .66, F(1, 30) = 56.9, P < .001)]. The PAQ-E and the ASI failed to enter into the 
equation. When the EMIA-A (T2) was removed from the equation the ASI (T2) failed to 
enter into the equation and the PAQ-E (T2) explained a significant portion of the variance 
[r2 change = .31, F(1, 30) = 13.2, P < .001)]. 
The BAI post-treatment ratings were significantly correlated with one expectancy measure: 








F value for 





Questionnaire (T3) 1 PAQ-E (T2) .60 .62*** 15.2 3, 28 .43*** 
  ASI (T2)     .13      
  EMIA-A(T2)     .07      
 2 PAQ (T1) .60 .01 .40 1, 27 .01      
Beck Depression 
Inventory (T3) 1 ASI (T2) .30 .31*** 12.8 1, 29 .31***   
  2 ASI (T1) .40 .08 3.8 1, 28 .08        
Note: Ns may vary from 31 to 32 due to missing data. 
ASI = Anxiety Sensitivity Index; PAQ-E = Panic Attack Questionnaire-Expectancy; EMIA-A = 
Expectancy Mobility Inventory for Agoraphobia. 
*p < .05, **p < .01, ***p< .001 
Table 6. Hierarchical Regression Analyses of Pre-treatment (T1) and Initial TreatmentPhase 
(T2) Expectancy Measures on Post-treatment (T3) Symptom Severity Measures 
3.5.4 Prediction of outcome measures 
Consistent with our last objective, we examined the contribution of expectancies above and 
beyond the contribution of symptoms on the outcome of PDA following cognitive-behavior 
therapy. Hierarchical regression analyses were used to compare the utility of 
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symptomatology versus expectancies in predicting symptomatology post-treatment scores. 
Initial treatment phase  (i.e., T2 or session 4) symptom and expectancy variables that were 
identified in the previous sections as significant predictors of post-treatment (i.e., T3) 
symptom severity were entered into the equation. Symptom measures were entered in the 
first block followed by expectancy measures in the second. Findings revealed that the 
addition of expectancy measures significantly added to the prediction model for most 
dependent measures except for the BAI (T3) and the BDI-II (T3) scores (see Table 7). 
To determine which individual measures were the best predictors of the symptom 
measures, stepwise regression analyses were performed. 
The regression analysis for the BSQ (T3) revealed that anxiety expectancy after the fourth 
session (PAQ-E T2) was the best predictor of the BSQ [r2 change = .61, F(1, 28) = 44.1, P < 
.001)]. The BSQ (T2) and the BAI (T2) failed to enter into the equation.  
 





F value for 





Questionnaire (T3) 1 BSQ (T2)  .53*** 15.1 2, 27 .18** 
  BAI (T2)    .13** 
 2 PAQ-E (T2) .14** 10.7 1, 26 .14**    
Agoraphobia 
Cognitions 
Questionnaire (T3) 1 BAI (T2) .40*** 8.8 2, 27 .18**  
  ACQ (T2)    .10*   
 2 PAQ-E (T2) .14* 3.6 2, 25 .02    
  EMIA-A (T2)    .07    
Mobility Inventory for 
Agoraphobia-Alone 
(T3) 1 MIA-A (T2) .59*** 41.5 1, 29 .59*** 
 2 EMIA-A (T2) .12** 12 1, 28 .12** 
Beck Anxiety 
Inventory (T3) 1 BAI (T2) .47*** 24.8 1, 28 .47*** 
 2 PAQ-E (T2) .04 2 1, 27 .04   
Beck Depression 
Inventory (T3) 1 BDI-II (T1) .32*** 14.2 1, 30 .32*** 
  2 ASI (T2) .09 4.2 1, 29 .09H   
Note: Ns may vary from 30 to 32 due to missing data. 
BSQ = Body Sensations Questionnaire (T3); ACQ = Agoraphobia Cognitions Questionnaire; BAI= Beck 
Anxiety Inventory; MIA-A = Mobility Inventory for Agoraphobia-Alone; BDI = Beck Depression 
Inventory; ASI = Anxiety Sensitivity Index; PAQ-E = Panic Attack Questionnaire-Expectancy; EMIA-A 
= Expectancy Mobility Inventory for Agoraphobia. 
*p < .05, **p < .01, ***p< .001;  
H
 p =.05 
Table 7. Hierarchical Regression Analyses of Expectancy vs Symptomatology as Predictors 
of Post-Treatment Severity  
We entered the BAI (T2), ACQ (T2), PAQ-E(T2) and the EMIA-A (T2) into a stepwise 
multiple regression analysis to determine the best predictor for the ACQ (T3). The PAQ-E 
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(T2) was the only significant predictor accounting for 37% of the variance [r2 change = .37, 
F(1, 28) = 16.4, P < .001)]. 
Finally, when the MIA-A (T2) and the EMIA-A (T2) are entered into a stepwise multiple 
regression with MIA-A (T3) as the dependent variable, the results show the EMIA-A (T2) 
enters significantly in the first step [r2 change = .65, F(1, 29) = 54.6, P < .001)], followed by 
the MIA-A (T2) [r2 change = .06, F(1, 28) = 5.7, P < .05)]. 
The above findings demonstrate that, for the most part, expectancies measured after four 
sessions (T2) are better predictors of PDA outcome, in contrast to initial treatment phase (T2) 
symptomatology. 
4. Discussion 
The objectives of this study were to examine (a) the relationship between expectancies (i.e., 
anxiety sensitivity and expectancy, and prognostic expectancy as measured by avoidance 
expectancy) and symptom severity (i.e., avoidance of specific situations, intensity of fear of 
somatic symptoms, frequency of agoraphobic cognitions, intensity of anxiety symptoms and 
levels of depressive symptoms) in panic disorder with agoraphobia (PDA) prior to 
treatment; (b) the impact of initial treatment phase scores in contrast to baseline scores on 
outcome; and (c) the contribution of expectancies above and beyond the contribution of 
symptoms on the outcome of PDA following a cognitive-behavior therapy.  
Consistent with our first hypothesis, and similar to other studies (e.g., Cox et al., 1991; 
McNally, & Lorenz, 1987; Norton et al., 1999; Schmidt, et al., 1997) we found that baseline 
severity of PDA symptomatology was predicted by higher anxiety sensitivity, and greater 
expectations of anxiety and expectations of avoidance behavior. Our findings were 
independent of duration of PDA, suggesting that individuals with PDA may hold these 
strong beliefs about their symptoms regardless of how long they have had PDA. The 
experience of panic may further validate their beliefs surrounding the occurrence and 
consequences of anxiety symptoms and avoidance behaviors  
As predicted in the first part of our second hypothesis, most of the initial treatment phase 
symptom scores were better predictors of PDA outcome. The only session 4 measure that 
did not significantly predict outcome was the BDI-II. Pre-treatment depressive symptoms 
were significant determinants of post-treatment scores on the BDI-II. This may suggest that 
regardless of the progress during group CBT for PDA, initial severity of depressive 
symptoms is the best predictor of mood following therapy. Clients suffering from PDA who 
also experience depressive symptoms may benefit from a therapy that includes a component 
aimed at addressing their depression.  
Consistent with the second part of our second hypothesis, expectancies measured after 
session four were significant determinants of post-treatment PDA symptom severity. This 
suggests that clients who failed to make the cognitive shifts in expectancies after four 
sessions of therapy were more likely to have a poor outcome. Our results are also in line 
with the earlier theories posited by Perotti and Hopewell (1980) and Weiner (1982) (both 
cited in Garfield, 1986) that indicate after being exposed to several sessions of therapy, 
expectations may shift towards a positive direction if clients perceive improvement, or they 
may shift towards a negative direction if no benefits are noticed. However, we cannot 
conclude that expectancies shifted as a result of symptoms improving. It is likely that initial 
expectations and/or maladaptive beliefs were disconfirmed after being exposed to several 
components of therapy. 
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Our final objective examined the contribution of expectancies in contrast to symptomatology 
on the outcome of PDA. The findings revealed that the addition of expectancy measures 
significantly added to the prediction of most post-treatment symptom measures except for 
anxiety severity (i.e., BAI-T3) and depressive symptoms (i.e., BDI-II-T3). The best predictor 
of anxiety (i.e,. BAI-T3) at post-treatment was level of anxiety (BAI-T2) in the initial phase of 
treatment. This suggests that a reduction in anxiety symptoms following therapy is best 
predicted by the level of anxiety after four sessions of treatment rather than expectancies of 
experiencing a panic attack in a particular situation (i.e., PAQ-E). Perhaps examining 
prognostic expectancies specifically related to panic (i.e., the probability of therapeutic 
success with respect to experiencing various panic symptoms; e.g., "Following therapy, I 
expect my symptoms related to shortness of breath to diminish") rather than expectancies of 
experiencing panic attacks in a particular situation (i.e., PAQ-E) may have demonstrated 
greater predictability in post-treatment anxiety severity as measured by the BAI.  
Post-treatment depressive symptoms were best predicted by baseline depressive symptoms. 
This implies that baseline severity and improvements from pre- to initial treatment phase in 
both PDA symptoms and expectancies are not predictive of post-treatment depressive 
symptoms.  However, participants with lower levels of anxiety sensitivity after four sessions 
showed trends towards improvement in post-treatment depressive symptoms. This is 
consistent with other studies that demonstrate the relationship of anxiety sensitivity and 
depression (e.g., Schmidt et al., 1998; Taylor et al., 1996). 
The remaining post-treatment symptom severity measures were best predicted by 
expectancy measures. A reduction in the fear of symptoms at the end of treatment (i.e., BSQ-
T3) was best predicted by the level of expected anxiety (PAQ-E-T2) after clients had already 
been exposed to several components of therapy. A greater proportion of the variance in the 
post-treatment frequency of agoraphobic cognitions (i.e., ACQ-T3) was explained by 
avoidance expectancy (EMIA-A-T2), followed by anxiety severity (BAI-T2) after four 
sessions of therapy. This suggests that at the end of therapy, a decrease in the frequency of 
phobic cognitions during a panic attack appears to be determined by lower levels of 
expectancy to avoid a specific situation and by a decrease in anxiety-related symptoms after 
session four. Finally, post-treatment agoraphobic avoidance (MIA-T3) was best predicted by 
avoidance expectancies (EMIA-A-T2), followed by actual avoidance (MIA-A-T2). 
The above findings appear to support the overprediction of fear model presented by 
Rachman (e.g., Rachman & Bichard, 1988; Rachman, 1994). The overprediction of fear 
implies that the predicted fear is greater than the actual experience of fear. Although we did 
not directly examine this phenomenon, there are some similarities in our findings. The 
clients in our study initially reported high levels of fear. However, after four sessions, their 
reported expectancy of experiencing panic attacks in several situations and their fear of 
anxiety-related sensations significantly diminished. These clients had not received any 
interoceptive or invivo exposure therapy at this point. It appears as though the majority of 
the participants in our study adjusted their expectations after they had received some 
corrective information with respect to their anxiety symptoms. Furthermore, greater 
accuracy in anxiety expectancies appeared to have had a better influence on most PDA 
outcome measures than the decrease in symptoms after four sessions. Another interesting 
finding was with respect to client's prognostic expectations (i.e., avoidance expectancy). 
There was no change from pre- to post-treatment. From the outset of therapy, most 
participants appeared to expect a fairly accurate outcome with respect to their avoidance 
behavior. When pre-treatment avoidance scores (M = 85.7) were compared with avoidance 
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expectancy scores (M = 52), our findings revealed significantly less expected avoidance than 
actual avoidance (p < .001). They did not appear to underpredict what would happen at the 
end of therapy with respect to their avoidance since there was no significant difference 
between pre-treatment avoidance expectancy scores and post-treatment avoidance scores 
(M = 49.4; p > .05). 
Overall, our results indicate that expectancies appear to be important predictors of PDA 
outcome following CBT. However, our findings did not detect anxiety sensitivity as an 
important determinant in PDA outcome. Anxiety sensitivity was detected as a good 
predictor of pre-treatment symptomatology. It may be suggested that anxiety sensitivity 
contributes to the development and relapse of PDA, but the effects of baseline and initial 
treatment phase anxiety sensitivity may not be evident until follow-up trials. Studies have 
demonstrated that ASI scores at the end of CBT for PDA predict relapse better than 
alternative measures (e.g., Brown & Barlow, 1995; Clarke et al., 1994). Future studies 
should also examine the impact of baseline and in-session anxiety sensitivity on relapse 
during follow-up.  
The above findings demonstrate that addressing expectancies at the beginning of therapy 
may help clients gain a better understanding regarding some of the factors that contribute to 
their anxiety. Exposure therapy may function as a reality test for such individuals. Exposing 
oneself to the feared stimuli (i.e., bodily sensations and feared situations) will gradually 
disconfirm previous negative expectations related to the harmful consequences of anxiety 
sensations (e.g., Kirsch et al., 1983). Cognitive techniques (Beck, 1988) are also important in 
modifying expectations or beliefs regarding the harmful consequences of anxiety sensations. 
Similar to the conclusions made by Salkovskis, Clark and Gelder (1996), it appears to be 
more important to address "what is being avoided" rather than simply trying to habituate 
clients to their anxiety symptoms because if they continue to believe that their symptoms are 
dangerous, panic symptoms will persist regardless of whether they are controlled through 
breathing techniques or relaxation.  
The measure of prognostic expectancy was adapted from the Mobility Inventory for  
Agoraphobia. Internal consistency of the measures was estimated but it is necessary to 
further validate it. Future studies should examine convergent validity of this measure in 
order to determine whether the questionnaires measured what it purported to measure. 
5. Conclusion 
Future research should assess expectancies prior to therapy and try to address some of these 
expectancies during the evaluation phase of treatment. For instance, providing clients with 
pre-treatment information on what should be expected in terms of the process and 
procedures of treatment and what the research has shown in terms of rate of improvement 
in PDA may result in an increase in treatment adherence and a decrease in levels of anxiety 
related to taking part in therapy (Deane et al., 1992; Webster, 1992). In light of the above 
findings, it appears important to examine how systematically modifying different types of 
expectations, as early as the beginning of the waiting period, by providing a pre-therapy 
modification expectancy video, can produce an impact on treatment outcome. Treatment 
improvement could also consist of addressing expectations early on in treatment, through a 
collaborative discussion-approach whereby clients' expectations and treatment objectives 
are identified in the initial session and a discussion process takes place between the 
therapist and the participants (Lazare et al., 1975). Combined, a pre-therapy video and a 
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collaborative discussion-approach could be centred on modifying initial expectations, a 
common active ingredient in most therapies (Lambert et al., 1986; Muran et al., 1995). 
Finally, it is quite evident that expectations play a major role in clients suffering from PDA. 
Preparing clients for psychotherapy by a systematic modification of expectancies may be 
associated with improved outcome. 
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